<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) plus <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A (CsA) is the standard treatment for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) patients not eligible for allogeneic hematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>In the absence of ATG + CsA, <z:chebi fb="5" ids="50113">androgens</z:chebi> continue to be a treatment option </plain></SENT>
<SENT sid="2" pm="."><plain>We documented the clinical evolution of AA patients treated with <z:chebi fb="1" ids="4315">danazol</z:chebi> instead of ATG + CsA </plain></SENT>
<SENT sid="3" pm="."><plain>AA patients lacking both, human leukocyte antigen-matched donor and access to IST, were treated with <z:chebi fb="1" ids="4315">danazol</z:chebi> and modern support therapy and compared with those receiving a HSCT </plain></SENT>
<SENT sid="4" pm="."><plain>Overall survival (OS), response rates, and <z:hpo ids='HP_0011420'>death</z:hpo> risk odds were calculated </plain></SENT>
<SENT sid="5" pm="."><plain>Fifty AA patients were studied </plain></SENT>
<SENT sid="6" pm="."><plain>Thirteen received a HSCT and 37 danazol and support therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Median daily dose of <z:chebi fb="1" ids="4315">danazol</z:chebi> was 400 mg (300 to 600 mg), administered during a median of 12 months </plain></SENT>
<SENT sid="8" pm="."><plain>Five-year OS was higher for patients receiving HSCT (92%) compared to the <z:chebi fb="1" ids="4315">danazol</z:chebi> group (41%) (P = 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Overall response rate was 46% (17/37) in the <z:chebi fb="1" ids="4315">danazol</z:chebi>-treated group and the median time to initial response was 3 months (1-27) </plain></SENT>
<SENT sid="10" pm="."><plain>Tendency to achieve remission was similar among severity groups (P���= 0.094) </plain></SENT>
<SENT sid="11" pm="."><plain>The only adverse side effect recorded on the <z:chebi fb="1" ids="4315">danazol</z:chebi> group was an episode of <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>No patient treated with <z:chebi fb="1" ids="4315">danazol</z:chebi> suffered <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e> of his/<z:e sem="disease" ids="C0017925" disease_type="Disease or Syndrome" abbrv="">her disease</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Although ATG plus CsA is the therapy of choice for AA patients without a donor when neither HSCT nor IST is available, <z:chebi fb="1" ids="4315">danazol</z:chebi> remains an acceptable therapeutic option for AA patients </plain></SENT>
</text></document>